Study of Safety, Tolerability and Pharmacokinetics of NRX-1074 in Normal Healthy Volunteers

NCT02366364 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

15

Enrollment

INDUSTRY

Sponsor class

Conditions

Major Depressive Disorder

Interventions

DRUG: Placebo
DRUG: NRX-1074 375 mg
DRUG: NRX-1074 500 mg
DRUG: NRX-1074 750 mg

Sponsor

Naurex, Inc, an affiliate of Allergan plc